View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsVivesto 過去の業績過去 基準チェック /06Vivestoは31.5%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで33.8%毎年増加している。売上は成長しており、年平均64.6%の割合である。主要情報31.49%収益成長率35.23%EPS成長率Biotechs 業界の成長17.04%収益成長率64.58%株主資本利益率-27.36%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新お知らせ • Nov 17+ 2 more updatesVivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024Vivesto AB announced that they will report nine months, 2024 results on Nov 21, 2024お知らせ • Nov 17+ 3 more updatesVivesto AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vivesto AB announced that they will report fiscal year 2023 results on Feb 23, 2024すべての更新を表示Recent updatesお知らせ • Jan 24Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offeringお知らせ • Nov 20Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offeringお知らせ • Nov 08Vivesto AB, Annual General Meeting, May 07, 2026Vivesto AB, Annual General Meeting, May 07, 2026. Location: stockholm Swedenお知らせ • Apr 08Vivesto AB, Annual General Meeting, May 08, 2025Vivesto AB, Annual General Meeting, May 08, 2025, at 09:00 W. Europe Standard Time. Location: at gustav iii:s boulevard 42, ground floor, se-169 73 solna, Swedenお知らせ • Apr 01Vivesto AB Reports Positive Cantrixil Results in an Animal Hematological Cancer ModelVivesto AB announced that positive preclinical efficacy data was obtained in an animal model of hematological cancer. The results support continued development of the candidate drug Cantrixil within this indication and are in line with previous positive preclinical data. The experimental trial demonstrates, for the first time, that Cantrixil can reduce tumor growth and increase survival times in a well-established mouse model of hematological cancer. The treatment was well tolerated and safe. With the new positive data, Vivesto is continuing the planning of activities needed to bring Cantrixil into clinical trials and in parallel will investigate opportunities to partner the project in order to optimize the development program.お知らせ • Jan 16Vivesto AB Receives Approval to Initiate A Dose-Finding Study of Paccal Vet in CatsVivesto AB announced that ethical approval has been obtained from the US Veterinary Review Board Clinical Studies Committee for a planned Paccal Vet dose-finding clinical trial in cats with cancer. The approval authorizes the participating clinical sites to enroll patients in the study. The dose-finding study will initially be conducted at two clinical sites in Washington and Oregon, with the possibility to include more sites as the study progresses. The study will be managed by CASTR Alliance, the contract research organization (CRO) currently running Paccal Vet's pilot clinical trial in dogs with splenic hemangiosarcoma in the US. FDA's Center for Veterinary Medicine, CVM, has previously confirmed that the cat study can be conducted under the existing INAD (Investigational New Animal Drug). The dose-finding study will follow the 3+3 design, a widely used approach to determine the maximum tolerated dose (MTD). A maximum of 12 cats will be included, receiving Paccal Vet treatment in groups of three, with doses escalating for each group until the MTD is identified. This study design ensures patient safety while effectively identifying the appropriate dosage for Paccal Vet administration in cats.お知らせ • Dec 20Vivesto Strengthens Cantrixil Program with New Preclinical Results and Patent ApplicationVivesto AB, announced that positive results were obtained from preclinical studies with combination treatments within the company’s Cantrixil program, supporting continued development in hematological cancer. Vivesto also announced that a new patent application covering the treatment of hematological cancer with Cantrixil was filed, with the aim to strengthen the IP position. The drug candidate Cantrixil has been evaluated in further combination treatments with other anti-cancer drugs generating new in vitro data in hematological cancer cell lines. The results demonstrate clear positive effects of Cantrixil in combination with other anti-cancer drugs. The positive results confirm previous preclinical efficacy results and support continued development in hematological cancer. New results from hematological cancer models are expected to be presented throughout 2025. Cantrixil has previously shown strong cytotoxic effects at low doses in cell lines derived from patients with hematological cancer. The recently generated data provides important input to the dosing selection and treatment regime in upcoming preclinical and clinical studies.お知らせ • Jan 30Vivesto's International Patent Application for XR-18 Receives Positive DecisionVivesto AB, announced that the European Patent Office (EPO) has granted a positive approval regarding the patentability of the company's XR-18 technology platform in Vivesto's international patent application (Patent Cooperation Treaty; PCT). The patent application for XR-18 is now in an international phase, which provides the opportunity to apply for patents in countries that are part of the PCT collaboration (157 countries). Vivesto now has two independent assessments that have been positive about the patentability of the XR-18 invention; EPO and earlier from the Swedish Intellectual Property Office (PRV). The company will now evaluate in which countries the company intends to seek protection.お知らせ • Dec 28Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient RecruitmentVivesto AB announced that the US Veterinary Review Board Clinical Studies Committee approved the company's planned Paccal Vet open label, pilot clinical study in dogs with splenic hemangiosarcoma following splenectomy. Clinical sites have been chosen and will be ready to start activities after supply of Paccal Vet (investigational veterinary product, IVP) in January. A planned interim analysis is expected in the second half of 2024. The Paccal Vet development program was discussed with FDA earlier this year. No further Agency approval is required prior to study start. The study is an open label, exploratory indication finding study in dogs with different stages of splenic hemangiosarcoma (HSA) following splenectomy. The study will include 4 treatment cycles of Paccal Vet (paclitaxel micellar) and it is planned to investigate 2 cohorts. Each cohort is planned to include a maximum of 23 patients. The study will be conducted at 6 clinical sites in Washington and Oregon. First patients are expected to be dosed in early 2024 and a planned interim analysis is expected in the second half of 2024. If promising activity in either cohort is shown, the study shall be followed by a pivotal study designed to confirm the initial findings of this pilot study and to gather further evidence on the safety and efficacy of Paccal Vet in dogs with splenic hemangiosarcoma. Vivesto's drug candidate Paccal Vet consists of paclitaxel formulated with the company's proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness.お知らせ • Nov 24Vivesto AB (publ) Announces Composition of Nomination CommitteeIn accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB's Annual General Meeting in 2022, it is hereby announced that the Nomination Committee for the 2024 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2023. The Nomination Committee for the 2024 Annual General Meeting comprises the following members: Per Arwidsson, appointed by Arwidsro, Håkan Lagerberg, appointed by Mastan AB, and Peter Zonabend, Chairman of the Board of Vivesto. Per Arwidsson has been appointed Chairman of the Nomination Committee.お知らせ • Nov 18Vivesto AB, Annual General Meeting, May 23, 2024Vivesto AB, Annual General Meeting, May 23, 2024.お知らせ • Nov 17+ 2 more updatesVivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024Vivesto AB announced that they will report nine months, 2024 results on Nov 21, 2024お知らせ • Aug 05Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar StudyVivesto AB announced early termination of patient enrollment in the Docetaxel micellar advanced prostate cancer Phase 1b study with the Swiss Group for Clinical Cancer Research (SAKK). The open-label, multicenter, single-stage Phase 1b study has closed its accrual after enrollment of 11 of the planned 18 patients, since Vivesto believes that the data generated will be sufficient ahead of switching into development with a new formulation based on its improved XR-18 micelle technology platform. Docetaxel mousellar has shown good tolerability at doses considered standard for conventional docetaxel formulations, as well as signs of clinical activity. Docetaxel miceLLar has been well received by investigators of the SAKK 67/20 and by participating prostate cancer patients. Vivesto's Docetaxel micellAR is a solvent-free formulation of docetaxel developed to avoid the need for the solubility enhancers in a solvent-based docetaxel and the mandatory high-dose steroid premedication. Patients treated with other existing formulations of docetaxel require steroid administration to avoid certain serious adverse events related to the formulations with solvent. The administration of steroids can lead to marked bone fragility, exacerbated by cancer metastases in the bone, or steroid-related metabolic issues. Vivesto has progressed in the development of its XR-18 drug delivery platform and intends to use this next-generation improved technology in future development of Docetaxel miceller.お知らせ • Nov 17+ 3 more updatesVivesto AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vivesto AB announced that they will report fiscal year 2023 results on Feb 23, 2024収支内訳Vivesto の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:OASM.Y 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Dec 250-3432030 Sep 250-3632030 Jun 250-3935031 Mar 250-4036031 Dec 240-4036030 Sep 247-9352030 Jun 247-9957031 Mar 247-11773031 Dec 237-12984030 Sep 232-28488030 Jun 233-34093031 Mar 233-35195031 Dec 223-35796030 Sep 2213-140101030 Jun 2224-99107031 Mar 2229-118111031 Dec 2129-133124030 Sep 21-184-34888030 Jun 21-195-354108031 Mar 21-199-376146031 Dec 204-210185031 Oct 20205-5983031 Jul 20205-2473030 Apr 20206-11226031 Jan 204-196113031 Oct 196-16785031 Jul 199-21060030 Apr 1910-20152031 Jan 1914-154107031 Oct 1813-153106031 Jul 1813-117106030 Apr 1812-118109031 Jan 1810-128115031 Oct 1710-139126031 Jul 178-155135030 Apr 177-160139031 Jan 177-151139031 Oct 1616-137141031 Jul 1619-139148030 Apr 1623-142156031 Jan 1626-139150031 Oct 1518-141136031 Jul 1519-124122030 Apr 1519-1171110質の高い収益: OASM.Yは現在利益が出ていません。利益率の向上: OASM.Yは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: OASM.Yは利益を出していないが、過去 5 年間で年間31.5%の割合で損失を削減してきた。成長の加速: OASM.Yの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: OASM.Yは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: OASM.Yは現在利益が出ていないため、自己資本利益率 ( -27.36% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/28 11:06終値2026/02/10 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vivesto AB 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Camilla OxhamreCarnegie Investment Bank ABKlas PalinDNB Carnegie Commissioned ResearchSusie JanaEdison Investment Research2 その他のアナリストを表示
お知らせ • Nov 17+ 2 more updatesVivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024Vivesto AB announced that they will report nine months, 2024 results on Nov 21, 2024
お知らせ • Nov 17+ 3 more updatesVivesto AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vivesto AB announced that they will report fiscal year 2023 results on Feb 23, 2024
お知らせ • Jan 24Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering
お知らせ • Nov 20Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering
お知らせ • Nov 08Vivesto AB, Annual General Meeting, May 07, 2026Vivesto AB, Annual General Meeting, May 07, 2026. Location: stockholm Sweden
お知らせ • Apr 08Vivesto AB, Annual General Meeting, May 08, 2025Vivesto AB, Annual General Meeting, May 08, 2025, at 09:00 W. Europe Standard Time. Location: at gustav iii:s boulevard 42, ground floor, se-169 73 solna, Sweden
お知らせ • Apr 01Vivesto AB Reports Positive Cantrixil Results in an Animal Hematological Cancer ModelVivesto AB announced that positive preclinical efficacy data was obtained in an animal model of hematological cancer. The results support continued development of the candidate drug Cantrixil within this indication and are in line with previous positive preclinical data. The experimental trial demonstrates, for the first time, that Cantrixil can reduce tumor growth and increase survival times in a well-established mouse model of hematological cancer. The treatment was well tolerated and safe. With the new positive data, Vivesto is continuing the planning of activities needed to bring Cantrixil into clinical trials and in parallel will investigate opportunities to partner the project in order to optimize the development program.
お知らせ • Jan 16Vivesto AB Receives Approval to Initiate A Dose-Finding Study of Paccal Vet in CatsVivesto AB announced that ethical approval has been obtained from the US Veterinary Review Board Clinical Studies Committee for a planned Paccal Vet dose-finding clinical trial in cats with cancer. The approval authorizes the participating clinical sites to enroll patients in the study. The dose-finding study will initially be conducted at two clinical sites in Washington and Oregon, with the possibility to include more sites as the study progresses. The study will be managed by CASTR Alliance, the contract research organization (CRO) currently running Paccal Vet's pilot clinical trial in dogs with splenic hemangiosarcoma in the US. FDA's Center for Veterinary Medicine, CVM, has previously confirmed that the cat study can be conducted under the existing INAD (Investigational New Animal Drug). The dose-finding study will follow the 3+3 design, a widely used approach to determine the maximum tolerated dose (MTD). A maximum of 12 cats will be included, receiving Paccal Vet treatment in groups of three, with doses escalating for each group until the MTD is identified. This study design ensures patient safety while effectively identifying the appropriate dosage for Paccal Vet administration in cats.
お知らせ • Dec 20Vivesto Strengthens Cantrixil Program with New Preclinical Results and Patent ApplicationVivesto AB, announced that positive results were obtained from preclinical studies with combination treatments within the company’s Cantrixil program, supporting continued development in hematological cancer. Vivesto also announced that a new patent application covering the treatment of hematological cancer with Cantrixil was filed, with the aim to strengthen the IP position. The drug candidate Cantrixil has been evaluated in further combination treatments with other anti-cancer drugs generating new in vitro data in hematological cancer cell lines. The results demonstrate clear positive effects of Cantrixil in combination with other anti-cancer drugs. The positive results confirm previous preclinical efficacy results and support continued development in hematological cancer. New results from hematological cancer models are expected to be presented throughout 2025. Cantrixil has previously shown strong cytotoxic effects at low doses in cell lines derived from patients with hematological cancer. The recently generated data provides important input to the dosing selection and treatment regime in upcoming preclinical and clinical studies.
お知らせ • Jan 30Vivesto's International Patent Application for XR-18 Receives Positive DecisionVivesto AB, announced that the European Patent Office (EPO) has granted a positive approval regarding the patentability of the company's XR-18 technology platform in Vivesto's international patent application (Patent Cooperation Treaty; PCT). The patent application for XR-18 is now in an international phase, which provides the opportunity to apply for patents in countries that are part of the PCT collaboration (157 countries). Vivesto now has two independent assessments that have been positive about the patentability of the XR-18 invention; EPO and earlier from the Swedish Intellectual Property Office (PRV). The company will now evaluate in which countries the company intends to seek protection.
お知らせ • Dec 28Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient RecruitmentVivesto AB announced that the US Veterinary Review Board Clinical Studies Committee approved the company's planned Paccal Vet open label, pilot clinical study in dogs with splenic hemangiosarcoma following splenectomy. Clinical sites have been chosen and will be ready to start activities after supply of Paccal Vet (investigational veterinary product, IVP) in January. A planned interim analysis is expected in the second half of 2024. The Paccal Vet development program was discussed with FDA earlier this year. No further Agency approval is required prior to study start. The study is an open label, exploratory indication finding study in dogs with different stages of splenic hemangiosarcoma (HSA) following splenectomy. The study will include 4 treatment cycles of Paccal Vet (paclitaxel micellar) and it is planned to investigate 2 cohorts. Each cohort is planned to include a maximum of 23 patients. The study will be conducted at 6 clinical sites in Washington and Oregon. First patients are expected to be dosed in early 2024 and a planned interim analysis is expected in the second half of 2024. If promising activity in either cohort is shown, the study shall be followed by a pivotal study designed to confirm the initial findings of this pilot study and to gather further evidence on the safety and efficacy of Paccal Vet in dogs with splenic hemangiosarcoma. Vivesto's drug candidate Paccal Vet consists of paclitaxel formulated with the company's proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness.
お知らせ • Nov 24Vivesto AB (publ) Announces Composition of Nomination CommitteeIn accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB's Annual General Meeting in 2022, it is hereby announced that the Nomination Committee for the 2024 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2023. The Nomination Committee for the 2024 Annual General Meeting comprises the following members: Per Arwidsson, appointed by Arwidsro, Håkan Lagerberg, appointed by Mastan AB, and Peter Zonabend, Chairman of the Board of Vivesto. Per Arwidsson has been appointed Chairman of the Nomination Committee.
お知らせ • Nov 18Vivesto AB, Annual General Meeting, May 23, 2024Vivesto AB, Annual General Meeting, May 23, 2024.
お知らせ • Nov 17+ 2 more updatesVivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024Vivesto AB announced that they will report nine months, 2024 results on Nov 21, 2024
お知らせ • Aug 05Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar StudyVivesto AB announced early termination of patient enrollment in the Docetaxel micellar advanced prostate cancer Phase 1b study with the Swiss Group for Clinical Cancer Research (SAKK). The open-label, multicenter, single-stage Phase 1b study has closed its accrual after enrollment of 11 of the planned 18 patients, since Vivesto believes that the data generated will be sufficient ahead of switching into development with a new formulation based on its improved XR-18 micelle technology platform. Docetaxel mousellar has shown good tolerability at doses considered standard for conventional docetaxel formulations, as well as signs of clinical activity. Docetaxel miceLLar has been well received by investigators of the SAKK 67/20 and by participating prostate cancer patients. Vivesto's Docetaxel micellAR is a solvent-free formulation of docetaxel developed to avoid the need for the solubility enhancers in a solvent-based docetaxel and the mandatory high-dose steroid premedication. Patients treated with other existing formulations of docetaxel require steroid administration to avoid certain serious adverse events related to the formulations with solvent. The administration of steroids can lead to marked bone fragility, exacerbated by cancer metastases in the bone, or steroid-related metabolic issues. Vivesto has progressed in the development of its XR-18 drug delivery platform and intends to use this next-generation improved technology in future development of Docetaxel miceller.
お知らせ • Nov 17+ 3 more updatesVivesto AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vivesto AB announced that they will report fiscal year 2023 results on Feb 23, 2024